Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

This study is testing a combination of two drugs — chidamide (an epigenetic drug that affects how genes are expressed) and linperlisibon (a PI3K inhibitor that targets cancer cell growth) — in patients with follicular lymphoma (a slow-growing type of blood cancer) that has stopped responding to previous treatments. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with follicular lymphoma (Grade 1 to 3a) - You have already received at least two prior treatments, with at least one including an anti-CD20 antibody drug (such as rituximab) - Your cancer has relapsed (come back) or is no longer responding to treatment - Your expected survival is more than 3 months - Your general health is adequate for treatment **You may NOT be eligible if...** - You have not previously received at least two treatments - Your lymphoma has transformed into a more aggressive type - Your organ function or overall health does not meet the requirements Talk to your doctor to see if this trial is right for you.